Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunotherapies Lead pneumococcal vaccine currently in clinical trials designed to provide broadest protection Product pipeline also includes first-in-class vaccines targeting healthcare-associated infections (HAIs) CAMBRIDGE, Mass., April 23, 2020-- Affinivax, Inc. ("Affinivax"), a clinical stage biotechnology company with its novel MAPS technology platform for vaccines and immunotherapies, today announced the completion of a $120 million Series B financing round, led by Viking Global Investors with participation from Bain Capital Life Sciences and Ziff Capital Partners.